Please assess the completion status of the following clinical trial:

Trial Title: S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic adenocarcinoma of the prostate~* Unresponsive or refractory to hormonal therapy, as defined by at least 1 of the following criteria:~  * Progression of bidimensionally measurable disease~ * Progression of evaluable but not measurable disease (bone scan)~ * At least 2 consecutive rises in PSA and a PSA level of at least 5 ng/mL~* No minimum PSA required for measurable disease or non-PSA evaluable disease~* Soft tissue disease that has been irradiated within the past 2 months is not considered measurable disease~* Prior orchiectomy OR~* Medical castration using leuprolide or goserelin~  * Luteinizing hormone-releasing hormone (LHRH) agonist therapy must continue during study~* Prior nonsteroidal antiandrogens (flutamide, ketoconazole, bicalutamide, or nilutamide) allowed if disease progression occurred~* No third-space fluid accumulation such as ascites or symptomatic pleural effusion~* No brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* SWOG 0-3~* Performance status 3 must be due to pain secondary to bone metastases~Life expectancy:~* Not specified~Hematopoietic:~* No hypercoagulability~Hepatic:~* Not specified~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No history of myocardial infarction~* No history of congestive heart failure unless well controlled~* No history of cerebrovascular accident or atrial fibrillation~* No active thrombophlebitis~* Left ventricular ejection fraction (LVEF) at least 50% by Multi Gated Acquisition Scan (MUGA) scan or 2-D echocardiogram~Pulmonary:~* No history of pulmonary embolus~Other:~* Recovered from major infections~* No other significant active medical illness~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer currently in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior biologic therapy and recovered~* No more than 1 prior biologic therapy regimen~* No concurrent biological response modifiers~Chemotherapy:~* At least 4 weeks since prior chemotherapy and recovered~* No more than 1 prior chemotherapy regimen~* No prior estramustine, taxanes, anthracyclines, or mitoxantrone~* No other concurrent chemotherapy~Endocrine therapy:~* See Disease Characteristics~* At least 4 weeks since prior flutamide or ketoconazole (6 weeks for bicalutamide or nilutamide)~* No concurrent corticosteroids or hormonal therapy (except megestrol for hot flashes or continuing LHRH treatment)~Radiotherapy:~* See Disease Characteristics~* Prior samarium Sm 153 lexidronam pentasodium allowed~* At least 4 weeks since prior radiotherapy and recovered~* No prior radiotherapy to 30% or more of bone marrow~* No prior strontium chloride Sr 89~* No concurrent radiotherapy~Surgery:~* See Disease Characteristics~* At least 3 weeks since prior surgery and recovered~Other:~* At least 4 weeks since prior bisphosphonates~* No prior anticoagulation therapy (i.e., warfarin), except aspirin~* No concurrent bisphosphonates

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel and Estramustine (Type: EXPERIMENTAL): Estramustine, 280 mg, PO, TID, Days 1-5; q 21 days Docetaxel, 60mg/m2, IV, Day 2; q 21 days
- Mitoxantrone and Prednisone (Type: ACTIVE_COMPARATOR): Mitoxantrone, 12 mg/m2, IV, Day 1; q 21 days Prednisone, 5 mg, PO, BID, Days 1-21; q 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).